These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9795915)

  • 1. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis.
    Davis GL; Beck JR; Farrell G; Poynard T
    J Viral Hepat; 1998 Sep; 5(5):313-21. PubMed ID: 9795915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.
    Bennett WG; Inoue Y; Beck JR; Wong JB; Pauker SG; Davis GL
    Ann Intern Med; 1997 Nov; 127(10):855-65. PubMed ID: 9382363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
    Wong JB; Bennett WG; Koff RS; Pauker SG
    JAMA; 1998 Dec 23-30; 280(24):2088-93. PubMed ID: 9875876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
    Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
    Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG
    Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
    Annemans L; Warie H; Nechelput M; Peraux B
    Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
    Wong JB; Davis GL; Pauker SG
    Am J Med; 2000 Apr; 108(5):366-73. PubMed ID: 10759092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.
    Kim WR; Poterucha JJ; Hermans JE; Therneau TM; Dickson ER; Evans RW; Gross JB
    Ann Intern Med; 1997 Nov; 127(10):866-74. PubMed ID: 9382364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R; Ghoshal UC; Naik SR
    Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.
    Buti M; Medina M; Casado MA; Wong JB; Fosbrook L; Esteban R
    Aliment Pharmacol Ther; 2003 Mar; 17(5):687-94. PubMed ID: 12641518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.
    Sagmeister M; Wong JB; Mullhaupt B; Renner EL
    Eur J Gastroenterol Hepatol; 2001 May; 13(5):483-8. PubMed ID: 11396525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness.
    Wong JB
    Acta Gastroenterol Belg; 1998; 61(2):238-42. PubMed ID: 9658620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.
    Siebert U; Sroczynski G; ;
    Int J Technol Assess Health Care; 2005; 21(1):55-65. PubMed ID: 15736515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C.
    Gheorghe L; Baculea S
    Hepatogastroenterology; 2010; 57(101):939-44. PubMed ID: 21033255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C: an economic evaluation of extended treatment with interferon.
    Shiell A; Brown S; Farrell GC
    Med J Aust; 1999 Aug; 171(4):189-93. PubMed ID: 10494234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.